Vectura Group plc (VEC) is a leading drug manufacturers-general business based in the UK. It opened the day at 107.2p after a previous close of 109.6p. During the day the price has varied from a low of 107.2p to a high of 111.4p. The latest price was 110.8p (25 minute delay). Vectura Group is listed on the London Stock Exchange (LSE) and employs 480 staff. All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, Vectura Group's share price has had significant positive movement.
Its last market close was 103.8p, which is 8.96% up on its pre-crash value of 94.5p and 75.63% up on the lowest point reached during the March crash when the shares fell as low as 59.1p.
If you had bought £1,000 worth of Vectura Group shares at the start of February 2020, those shares would have been worth £763.44 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,116.13.
|52-week range||59.1p - 127.4p|
|50-day moving average||111.6706p|
|200-day moving average||106.5796p|
|Wall St. target price||124.18p|
|Dividend yield||N/A (7.22%)|
|Earnings per share (TTM)||-11.8p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|3 months (2020-10-16)||6.74%|
|6 months (2020-07-17)||10.80%|
|2 years (2019-01-14)||inf%|
|3 years (2018-01-14)||inf%|
|5 years (2016-01-14)||inf%|
Valuing Vectura Group stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vectura Group's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Vectura Group's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £35.1 million.
The EBITDA is a measure of a Vectura Group's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||£176.3 million|
|Gross profit TTM||£95.3 million|
|Return on assets TTM||-0.12%|
|Return on equity TTM||-1.6%|
|Market capitalisation||£735.3 million|
TTM: trailing 12 months
We're not expecting Vectura Group to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Vectura Group's shares were split on a 12:13 basis on 14 October 2019. So if you had owned 13 shares the day before before the split, the next day you'd have owned 12 shares. This wouldn't directly have changed the overall worth of your Vectura Group shares – just the quantity. However, indirectly, the new 8.3% higher share price could have impacted the market appetite for Vectura Group shares which in turn could have impacted Vectura Group's share price.
Over the last 12 months, Vectura Group's shares have ranged in value from as little as 59.1p up to 127.4p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Vectura Group's is 0.292. This would suggest that Vectura Group's shares are less volatile than average (for this exchange).
Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ever wondered how to buy shares in Van Elle Holdings? We explain how and compare a range of providers that can give you access to many brands, including Van Elle Holdings.
Ever wondered how to buy shares in ULS Technology? We explain how and compare a range of providers that can give you access to many brands, including ULS Technology.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.